Effect of ivabradine on recurrent hospitalization for worsening heart failure in patients with chronic systolic heart failure: the SHIFT Study

被引:113
|
作者
Borer, Jeffrey S. [1 ,2 ]
Boehm, Michael [3 ]
Ford, Ian [4 ]
Komajda, Michel [5 ]
Tavazzi, Luigi [6 ]
Lopez Sendon, Jose [7 ]
Alings, Marco [8 ]
Lopez-de-Sa, Esteban [7 ]
Swedberg, Karl [9 ]
机构
[1] Suny Downstate Med Ctr, Dept Med, Brooklyn, NY 10128 USA
[2] Suny Downstate Med Ctr, Dept Med, New York, NY 10128 USA
[3] Univ Saarlandes Kliniken, Innere Med Klin 3, Homburg, Germany
[4] Univ Glasgow, Robertson Ctr Biostat, Glasgow, Lanark, Scotland
[5] Univ Paris 06, Dept Cardiol, Hop La Pitie Salpetriere, Paris, France
[6] Ettore Sansavini Hlth Sci Fdn, Maria Cecilia Hosp GVM Care & Res, Cotignola, Italy
[7] UAM, Dept Cardiol, Hosp Univ La Paz, IdiPaz, Madrid, Spain
[8] Hosp Amphia Ziekenhuis, NL-4818 CK Breda, Netherlands
[9] Univ Gothenburg, Dept Emergency & Cardiovasc Med, Sahlgrenska Acad, Gothenburg, Sweden
关键词
Heart failure; Hospitalization; Ivabradine; Left ventricular systolic dysfunction; Heart rate; CARDIAC RESYNCHRONIZATION THERAPY; SUBSEQUENT MORTALITY; RESOURCE UTILIZATION; REDUCTION; RISK; CANDESARTAN; CARVEDILOL; DIAGNOSIS; EVENTS; TRIAL;
D O I
10.1093/eurheartj/ehs259
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
We explored the effect of treatment with ivabradine, a pure heart rate-slowing agent, on recurrent hospitalizations for worsening heart failure (HF) in the SHIFT trial. SHIFT was a double-blind clinical trial in which 6505 patients with moderate-to-severe HF and left ventricular systolic dysfunction, all of whom had been hospitalized for HF during the preceding year, were randomized to ivabradine or to placebo on a background of guideline-recommended HF therapy (including maximized -blockade). In total, 1186 patients experienced at least one additional HF hospitalization during the study, 472 suffered at least two, and 218 suffered at least 3. Patients with additional HF hospitalizations had more severe disease than those without. Ivabradine was associated with fewer total HF hospitalizations [902 vs. 1211 events with placebo; incidence rate ratio, 0.75, 95 confidence interval (CI), 0.650.87, P 0.0002] during the 22.9-month median follow-up. Ivabradine-treated patients evidenced lower risk for a second or third additional HF hospitalization [hazard ratio (HR): 0.66, 95 CI, 0.550.79, P 0.001 and HR: 0.71, 95 CI, 0.540.93, P 0.012, respectively]. Similar observations were made for all-cause and cardiovascular hospitalizations. Treatment with ivabradine, on a background of guidelines-based HF therapy, is associated with a substantial reduction in the likelihood of recurrent hospitalizations for worsening HF. This benefit can be expected to improve the quality of life and to substantially reduce health-care costs.
引用
收藏
页码:2813 / 2820
页数:8
相关论文
共 50 条
  • [31] Effects of Heart Rate Reduction in Black Patients from the SHIFT (Systolic Heart Failure treatment with the If Inhibitor Ivabradine Trial) Study
    Borer, Jeffrey S.
    Komajda, Michel
    Ford, Ian
    Tavazzi, Luigi
    Dominjon, Fabienne
    Maya, Juan
    Wu, Yuna
    Depre, Christophe
    Boehm, Michael
    JOURNAL OF CARDIAC FAILURE, 2015, 21 (08) : S45 - S45
  • [32] Heart Rate Reduction with Ivabradine in Patients with Acute Decompensated Systolic Heart Failure
    Sargento, Luis
    Satendra, Milan
    Longo, Susana
    Lousada, Nuno
    dos Reis, Roberto Palma
    AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS, 2014, 14 (03) : 229 - 235
  • [33] Heart Rate Reduction with Ivabradine in Patients with Acute Decompensated Systolic Heart Failure
    Luis Sargento
    Milan Satendra
    Susana Longo
    Nuno Lousada
    Roberto Palma dos Reis
    American Journal of Cardiovascular Drugs, 2014, 14 : 229 - 235
  • [34] Influence of Worsening Heart Failure During Hospitalization on the Prognosis in Patients with Acute Decompensated Heart Failure
    Yamamoto, Erika
    Kato, Takao
    Yaku, Hidenori
    Morimoto, Takeshi
    Inuzuka, Yasutaka
    Tamaki, Yodo
    Ozasa, Neiko
    Sato, Yukihito
    Kuwahara, Koichiro
    Kimura, Takeshi
    CIRCULATION, 2021, 144
  • [35] Efficacy of ivabradine therapy on right heart parameters and prognosis in patients with severe systolic chronic heart failure
    Tumasyan, L. R.
    Adamyan, K. G.
    Chilingaryan, A. L.
    EUROPEAN HEART JOURNAL, 2012, 33 : 808 - 808
  • [36] Ivabradine in acute decompensated systolic heart failure
    Sargento, Luis
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 235 : 197 - 197
  • [37] Ivabradine in acute decompensated systolic heart failure
    Jose Hidalgo, Francisco
    Anguita, Manuel
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 235 : 198 - 198
  • [38] Ivabradine - well tolerated in elderly patients with systolic heart failure
    Zivlas, Christos
    Foley, Paul W. X.
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 249 : 330 - 331
  • [39] Efficacy and Safety of Ivabradine in Japanese Patients With Chronic Heart Failure - J-SHIFT Study -
    Tsutsui, Hiroyuki
    Momomura, Shin-ichi
    Yamashina, Akira
    Shimokawa, Hiroaki
    Kihara, Yasuki
    Saito, Yoshihiko
    Hagiwara, Nobuhisa
    Ito, Hiroshi
    Yano, Masafumi
    Yamamoto, Kazuhiro
    Ako, Junya
    Inomata, Takayuki
    Sakata, Yasushi
    Tanaka, Takashi
    Kawasaki, Yasushi
    CIRCULATION JOURNAL, 2019, 83 (10) : 2049 - +
  • [40] Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study
    Boehm, Michael
    Borer, Jeffrey
    Ford, Ian
    Gonzalez-Juanatey, Jose R.
    Komajda, Michel
    Lopez-Sendon, Jose
    Reil, Jan-Christian
    Swedberg, Karl
    Tavazzi, Luigi
    CLINICAL RESEARCH IN CARDIOLOGY, 2013, 102 (01) : 11 - 22